Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide for Ischemia/Reperfusion Injury in Neonatal CPB
NCT02151877Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2014
- Primary completion
- Aug 2018
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Randomised, double-blind trial of nitric oxide in ischemia-reperfusion injury (IRI) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Change in Biochemical Markers of Ischemia/Reperfusion Injury and Oxidative Damage. Started Jul 2014; status: completed.
02
Drugs
nitric oxide
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT02151877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151877.